购物车
- 全部删除
您的购物车当前为空
(4)
通过 货期 筛选 - 现货
- 5日内发货(58)
- 20日内发货(1)
- 待询(1)
筛选
已筛选:全部清除
通过 货期 筛选 
通过 种属 筛选 - Human(61)
通过 表达系统 筛选 - HEK293 Cells(38)
- E. coli(23)
通过 标签 筛选 - C-His-Avi(51)
- N-His(5)
- N-6xHis(3)
- N-GST(1)
通过 SPR兼容缓冲液 筛选 - 可直接使用(51)
- 需置换缓冲液(9)
- 可置换缓冲液(1)
筛选
搜索结果
TargetMol产品目录中 "
k-ras2
"的结果- 重组蛋白61
- KRAS Protein, Human, Recombinant (His)
对比RASK2, KRAS2, K-Ras 2, KRAS, Ki-Ras, GTPase KRas, c-K-ras, c-Ki-rasTMPH-01418Expression system: E. coli
Length: 2-168, Partial
Activity: Not Tested- ¥ 1320
规格数量可置换缓冲液 - KRAS Protein, Human, Recombinant (G12C, His)对比RASK2, KRAS2, Ki-Ras, c-K-ras, CFC2TMPJ-00510KRAS Protein, Human, Recombinant (G12C, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 26 KDa and the accession number is AAH13572.1.
- ¥ 320
规格数量SPR兼容缓冲液 - KRAS Protein, Human, Recombinant (G12V, His)对比RASK2, KRAS2, Ki-Ras, c-K-ras, CFC2TMPJ-00511KRAS Protein, Human, Recombinant (G12V, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 25-30 KDa and the accession number is AAH13572.1.
- ¥ 320
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01399Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- ¥ 6300
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01400Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- ¥ 6300
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01401Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- ¥ 4200
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01402Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 6300
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01403Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 4200
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01404Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 6300
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01405Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 4200
规格数量SPR兼容缓冲液 - HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01407Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- ¥ 6300
规格数量SPR兼容缓冲液 - HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01408Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 6300
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01427Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 6300
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01428Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 4200
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01429Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 6300
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01430Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 4200
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi)对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01431Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 12600
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01432Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 12600
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01433Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 12600
规格数量SPR兼容缓冲液 - HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01434Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 12600
规格数量SPR兼容缓冲液 - HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01435Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 18900
规格数量 - HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01438Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
- ¥ 18900
规格数量 - HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01439Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 18900
规格数量 - HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled对比RASK2, RALD, NS3, NS, MHC, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-Ras 2, KRAS, KI-RAS, GTPase Kras, C-K-RAS, CFC2TMPK-01443Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- ¥ 5670
规格数量SPR兼容缓冲液
产品对比
| 产品 |
|---|
| 生物活性 |
| 种属 |
| 表达系统 |
| 标签 |
| 蛋白编号 |
| 氨基酸序列 |
| 蛋白构建 |
| 蛋白纯度 |
| 分子量 |
| 内毒素 |
| 缓冲液 |
| 复溶方法 |
| 存储 |
| 运输条件 |
| 研究背景 |
| 价格 |
嗨！有任何问题？点我咨询
